Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults

Clinical Therapeutics

Volumn 37, Issue 9, 2015, Pages 2007-2018

  Nakamaru, Yoshinobu ^a   Hayashi, Yoshiharu ^a   Davies, Martin ^b   Jürgen Heuer, Horst ^c   Hisanaga, Noriko ^a   Akimoto, Kei ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b Mitsubishi Pharma Europe Ltd   (United Kingdom)

^c Nuvisan GmbH   (Germany)

Author keywords

dipeptidyl peptidase 4 inhibitor; drug drug interactions; metformin; pharmacokinetics; teneligliptin

Indexed keywords

AMINOTRANSFERASE; METFORMIN; ORGANIC CATION TRANSPORTER 2; QUINIDINE; TENELIGLIPTIN; 3-(4-(4-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)PIPERAZIN-1-YL)PYRROLIDIN-2-YLCARBONYL)THIAZOLIDINE; PYRAZOLE DERIVATIVE; THIAZOLIDINE DERIVATIVE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG INDUCED HEADACHE; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NAUSEA; NONHUMAN; NORMAL HUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; REPEATED DRUG DOSE; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; BLOOD; CLINICAL TRIAL; DRUG INTERACTION; MIDDLE AGED; YOUNG ADULT;

ADULT; AREA UNDER CURVE; DRUG INTERACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; METFORMIN; MIDDLE AGED; PYRAZOLES; THIAZOLIDINES; YOUNG ADULT;

EID: 84941166485     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.06.012     Document Type: Article

References (23)

1. B. Kreymann, G. Williams, M.A. Ghatei, and et al. Glucagon-like peptide-1 7-36: a physiological incretin in man Lancet 2 1987 1300 1304
2. C.M. Edwards, J.F. Todd, M. Mahmoudi, and et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39 Diabetes 48 1999 86 93
3. J. Buteau, S. Foisy, C.J. Rhodes, and et al. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation Diabetes 50 2001 2237 2243
4. G. Xu, D.A. Stoffers, J.F. Habener, and et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 1999 2270 2276
5. A. Wettergren, B. Schjoldager, P.E. Mortensen, and et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man Dig Dis Sci 38 1993 665 673
6. A. Flint, A. Raben, A. Astrup, and et al. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans J Clin Invest 101 1998 515 520
7. C.F. Deacon, M.A. Nauck, M. Toft-Nielsen, and et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects Diabetes 44 1995 1126 1131
8. J.J. Holst, and C.F. Deacon Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes Diabetes 47 1998 1663 1670
9. Y. Nakamaru, Y. Hayashi, R. Ikegawa, and et al. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans Xenobiotica 44 2014 242 253
10. Y. Nakamaru, Y. Hayashi, M. Sekine, and et al. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany Clin Ther 36 2014 760 769
11. A. Halabi, H. Maatouk, K.E. Siegler, and et al. Pharmacokinetics of teneligliptin in subjects with renal impairment Clin Pharmacol Drug Develop 2 2013 246 254
12. Y. Nakamaru, C. Emoto, M. Shimizu, and H. Yamazaki Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling Biopharm Drug Dispos 36 2015 148 162
13. GLUCOPHAGE® (metformin hydrochloride tablets), GLUCOPHAGE® XR (metformin hydrochloride extended-release tablets). Approved label. Bristol-Myers Squibb/Merck Santé S.A.S. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/020357s031,021202s016lbl.pdf [Last accessed February 10, 2015].
14. A.J. Scheen Clinical pharmacokinetics of metformin Clin Pharmacokinet 30 1996 359 371
15. N. Kimura, M. Okuda, and K. Inui Metformin transport by renal basolateral organic cation transporter hOCT2 Pharm Res 22 2005 255 259
16. Y. Tanihara, S. Masuda, T. Sato, and et al. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters Biochem Pharmacol 74 2007 359 371
17. S. Masuda, T. Terada, A. Yonezawa, and et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2 J Am Soc Nephrol 17 2006 2127 2135
18. T.B. Stage, P. Damkier, R.S. Pedersen, and et al. A twin study of the trough plasma steady-state concentration of metformin Pharmacogenet Genomics 25 2015 259 262
19. H. Kusuhara, S. Ito, Y. Kumagai, and et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects Clin Pharmacol Ther 89 2011 837 844
20. Y.L. He, R. Sabo, F. Picard, and et al. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes Curr Med Res Opin 25 2009 1265 1272
21. C.G. Patel, D. Kornhauser, N. Vachharajani, and et al. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects Diabetes Obes Metab 13 2011 604 614
22. A. Karim, P. Covington, R. Christopher, and et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects Int J Clin Pharmacol Ther 48 2010 46 58
23. M.K. Kim, E.J. Rhee, K.A. Han, and et al. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial Diabetes Obes Metab 17 2015 309 312